SCHEMBL22729595

SCHEMBL22729595

Cc1cn(C)c(=O)c2c(C(=O)NCc3ccccc3)csc12

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.58
CNR1 P21554 2/20 0.47
CNR2 P34972 2/20 0.47
ALDH1A1 P00352 3/20 0.46
HPGD P15428 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HSD17B10 Q99714 1/20 0.46
HTT P42858 1/20 0.45
TRPA1 O75762 1/20 0.45
KMT2A Q03164 4/20 0.44
MEN1 O00255 3/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
LIPG Q9Y5X9 1/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22729486 0.80 BRD4 (0.65) BRD4CNR1CNR2ALDH1A1HPGD
SCHEMBL22729749 0.79 ADORA2A (0.44) BRD4ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL22729775 0.79 MAP2K1 (0.43) BRD4CNR1CNR2ALDH1A1HPGD
SCHEMBL22729400 0.77 BCAT2 (0.38) BRD4HPGDKMT2AMEN1POLB
SCHEMBL16047461 0.75 ALDH1A1 (0.48) BRD4ALDH1A1HTTTRPA1POLB
SCHEMBL13591317 0.74 BRD4 (0.67) BRD4CNR1CNR2ALDH1A1HPGD
SCHEMBL2736514 0.71 BRD4 (0.66) BRD4CNR1CNR2ALDH1A1HPGD
SCHEMBL2736515 0.71 BRD4 (0.66) BRD4CNR1CNR2ALDH1A1HPGD
Trifluoroacetic Acid SCHEMBL16043582 0.70 ALDH1A1 (0.46) BRD4ALDH1A1HTTCYP3A4POLB
SCHEMBL16658359 0.70 BRD4 (0.76) BRD4CNR1CNR2ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459325-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-10-04 US disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 US disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 US disclosed
EP-3747885-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-12-09 EP disclosed
EP-3747885-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087186-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC BRD4 1170/4885CNR1 856/4885CNR2 801/4885
US-11459325-B2 Heterocyclic compound GBA1, GBA2, GALC BRD4 1201/4885CNR1 851/4885CNR2 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.